Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 14/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5301595 | 1.00 | FDPS (0.43) | FDPS | |
| SCHEMBL29012433 | 1.00 | FDPS (0.43) | FDPS | |
| SCHEMBL28904337 | 1.00 | FDPS (0.43) | FDPS | |
| SCHEMBL4486157 | 1.00 | FDPS (0.43) | FDPS | |
| SCHEMBL28390378 | 1.00 | FDPS (0.43) | FDPS | |
| SCHEMBL669819 | 1.00 | FDPS (0.43) | FDPS | |
| SCHEMBL6264031 | 1.00 | FDPS (0.43) | FDPS | |
| Phosphoric Acid SCHEMBL28999646 | 0.95 | FDPS (0.46) | FDPS | |
| Phosphoric Acid SCHEMBL29088148 | 0.95 | FDPS (0.46) | FDPS | |
| SCHEMBL617158 | 0.94 | FDPS (0.41) | FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220775-A1 | ENANTIOSELECTIVE PREPARATION OF QUINOLINE DERIVATIVES | LOHSE OLIVIER (FR) | 2012-08-30 | — | — | US | disclosed |
| US-7605267-B2 | Process for the preparation of 5-(halocetyl)-8-(substituted oxy)-(1h)-quinolin-2-ones | NOVARTIS AG (CH) | 2009-10-20 | — | — | US | disclosed |
| US-20060189653-A1 | Process for the preparation of 5-(halocetyl)-8-(substituted oxy)-(1h)-quinolin-2-ones | NOVARTIS AG (CH) | 2006-08-24 | — | — | US | disclosed |
| EP-1182196-B1 | Halogen-free preparation of ionic fluids | SOLVENT INNOVATION GMBH (DE) | 2004-06-30 | — | — | EP | disclosed |
| EP-1182196-A1 | Halogenide-free preparation of ionic fluids | Solvent Innovation GmbH (DE) | 2002-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220775-A1 | ENANTIOSELECTIVE PREPARATION OF QUINOLINE DERIVATIVES | OPRM1, OPRD1, HAX1 | FDPS 4013/4885 |
| US-20060189653-A1 | Process for the preparation of 5-(halocetyl)-8-(substituted oxy)-(1h)-quinolin-2-ones | UGT8, KAT8, UGT1A8 | FDPS 2849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.